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Abstract 
Interleukin-I (IL-I) stimulates a time- and concentration-dependent mitogen-activated protein (MAP) kinase activation in rat mesangial cells. A 
rapid increase in activity (maximal at 10 min) is followed by a second persistent level of activity which steadily increases over 24 h. The second peak 
of MAP kinase activity is paralleled by a marked de novo synthesis of p42 MAP kinase as measured by immunoprecipitation of [35S]methionine- 
labelled mesangial cells and by a 60% increase in total p42 MAP kinase protein as detected by Western blot analysis. We propose that IL-1 induced 
de novo synthesis of p42 MAP kinase is important for the multiplicity of long-term actions of this cytokine in renal mesangial cells. 
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1. Introduction 
Interleukin 1 (IL-l) is the prototype of an inflamma- 
tory cytokine that induces the expression of a variety of 
protein factors that, in turn, trigger acute and chronic 
inflammatory processes [l]. The local release of growth 
factors such as IL-l or tumour necrosis factor a from 
monocytes is an early event associated with inflamma- 
tory reactions and may be an important pathogenetic 
determinant of structural and functional alterations ac- 
companying immune injury in many organs including 
the kidney [I]. 
The mesangium is a highly specialized pericapillary 
tissue that is involved in most pathological processes of 
the renal glomerulus. The cross-talk between intrinsic 
glomerular cells and invading immune cells is of central 
importance in the pathogenesis of glomerular injury. 
Three prominent features of intrinsic mesangial cells 
evolve as a result of the cross-communication with in- 
vading monocytes and macrophages: increased media- 
tors production, increased matrix synthesis and in- 
creased mesangial cell proliferation [2]. IL-l has been 
reported to stimulate the release of a specific type IV 
collagenase [3], of a group II phospholipase A, [4-61, and 
of prostaglandins [4,7,8] by mesangial cells. IL-l also 
triggers the expression of an inducible macrophage-type 
of nitric oxide synthase [9,10] and a variety of chemoki- 
nes and cytokines [ 1 I] in mesangial cells. Moreover, IL- 1 
is a co-mitogen in cultured mesangial cells [12,13] and 
stimulates the rapid phosphorylation of several proteins 
in the cells [14]. The signalling pathways of IL-l linking 
receptor occupancy to cellular responses are not yet 
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known. The IL-l receptor has no intrinsic tyrosine ki- 
nase activity and it has been demonstrated that IL-l does 
not activate protein kinase C or protein kinase A in 
mesangial cells [ 151. Nevertheless, one of the earliest cel- 
lular responses observed after IL- 1 exposure is the phos- 
phorylation of a variety of proteins in mesangial cells 
and other cell types. Recently, IL-l has been shown to 
induce mitogen-activated protein (MAP) kinase activity 
in fibroblasts and the human epidermoid carcinoma cell 
line KB [16-181. MAP kinases are important intermedi- 
ates in signal transduction pathways stimulated by 
growth factors, hormones, neurotransmitters and mito- 
genie agents [19-211. To date, three distinct MAP kinases 
have been isolated. p44 MAP kinase and p42 MAP ki- 
nase are closely related to each other, whereas the third 
form encodes a more distantly related kinase that is only 
42% homologous to p44 MAP kinase [19-211. MAP ki- 
nases appear to be highly conserved across species which 
may attest their important functions in signalling proc- 
esses. Activation of MAP kinases results from phospho- 
rylation of adjacent Tyr and Thr residues within MAP 
kinase by a dual specificity protein kinase termed MAP 
kinase kinase [19-211. 
Here we show that IL-l stimulates a biphasic activa- 
tion of MAP kinase activity in mesangial cells and in- 
duces a marked de novo synthesis of p42 MAP kinase. 
To our knowledge, this is the first report on increased 
biosynthesis of MAP kinase in response to agonist stim- 
ulation. 
2. Materials and methods 
2. I. Cell culture 
Rat renal mesangial cells were cultivated as described previously 
[4,10]. In a second step, single cells were cloned by limited dilution on 
96-microwell plates. Clones with apparent mesangial cell morphology 
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were used for further processing. The cells were grown in RPM1 1640 
supplemented with 10% (v/v) fetal-calf serum, penicillin (100 units/ml), 
streptomycin (100 &ml) and bovine insulin (0.66 units/ml). For the 
reported experiments, passages 8-19 of mesangial cells were used. 
2.2. MBP kinase assay 
Quiescent mesangial cells in 60 mm-diameter dishes were stimulated 
with the indicated concentrations of agonists. To stop the reaction, the 
cells were washed with PBS and scraped into 0.5 ml of kinase buffer 
(20 mM Tris-HCI, pH 7.5/l mM EGTA/Z mM MnCl,/O.l mM sodium 
orthovanadatell mM phenylmethanesulphonyl fluoride/25 /&ml 
leupeptin). Cells were then homogenized by passes through a 26-gauge 
needle, centrifuged for 5 min at 14,000 x g and then supernatant was 
taken for determination of protein concentration. 50 pg of cell extracts 
were incubated for 15 min at 30°C in the presence of 20 pg of MBP, 
10 PM ATP and 2 @i [Y-~~P]ATP. The reaction was terminated by 
adding 40 ~1 Laemmli dissociation buffer and subjected to SDS-PAGE 
(13% acrylamide gel). After fixing in 25% isopropanol, 10% acetic acid, 
the gels were exposed to Hyperfdm MP for 3-5 h. 
2.3. Cell labelling and immunoprecipitation 
Confluent mesangial cells in 100 mm diameter dishes were washed 
with PBS and incubated in methionine-free DMEM in the absence or 
presence of the stimulators for the indicated time periods. For the last 
4 h of incubation [‘Slmethionine was’ added (100 PCilplate). After 
labeling, cells were-washed twice with icecold PBS.. Cells were then 
scraued directlv into 1 ml of ice-cold lvsis buffer (50 mM Tris-HCI. DH 
7.5/i50 mM-NaCl/lO% glycerol/l% Triton X-100/2 mM EDTA/Z mM 
EGTA/40 mM b-glycerophosphatel50 mM sodium fluoride/l0 mM 
sodium pyrophosphate1200 PM sodium orthovanadate/lO fig of 
leupeptin/mY200 U of aprotinin/ml/l PM pepstatin A/l mM phen- 
ylmethanesulphonyl fluoride) and homogenized with 10 passes through 
a 26-gauge needle. The homogenate was centrifuged for 10 min at 
14,000 x g and the supernatant taken for immunoprecipitation. Sam- 
ples of 1 ml volume, containing 100 x IO6 cpm of labelled proteins, 5% 
fetal calf serum and 1.5 mM iodoacetamide in lysis buffer, were incu- 
bated for 4 h at 4°C with a specific p42 MAP kinase antibody [22], 
diluted as indicated in the figure legends. Then 100 ~1 of a 50% slurry 
of protein A-Sepharose 4B-CL in PBS was added and the mixture was 
incubated for 1.5 h at room temperature under mild shaking. After 
centrifugation for 5 min at 3000 xg immunocomplexes were washed 3 
times with 1 ml of a low salt buffer (50 mM Tris-HCl, pH 7.5/150 mM 
NaC1/0.2% Triton X-100/2 mM EDTA/2 mM EGTA/O.l% SDS), 3 
times with 1 ml of a high salt buffer (50 mM Tris-HCJ, pH 7.5/500 mM 
NaC1/0.2% Triton X-10012 mM EDTA/Z mM EGTA/O.I% SDS) and 
once with 1 ml of 10 mM Tris. Pellets were boiled for 5 min in 50 ~1 
Laemmli dissociation buffer and subjected to SDS-PAGE (10% 
acrylamide gel). After fixing in 25% isopropanol/lO% acetic acid, the 
gels were soaked for 30 min in 16% sodium salicylate solution and then 
dried and exposed to Hyperhlm MP at -70°C. 
2.4. Chemicals 
Protein A-Sepharose 4B-CL war purchased from Pharmacia Fine 
Chemicals, Uppsala, Sweden; [?S]methionine (specific activity 55.5 
TBqlmmol), [92P]orthophosphate nd hyperfilm MP were from Amer- 
sham International, Zurich, Switzerland; human recombinant IL-Ip 
was kindly provided by Dr. Klaus Vosbeck, Ciba Ltd., Basel, Switzer- 
land; A antiserum which specifically recognized the p42-isoform was 
kindly provided by Dr. M.J. Dunn, Cleveland (al, CP42) [22], all cell 
culture nutrients were from Gibco BRL, Basel, Switzerland; all other 
chemicals were from Merck, Darmstadt, Germany or Fluka, Buchs, 
Switzerland. 
3. Results 
IL-lp is a potent stimulator of MAP kinase activity in 
mesangial cells and induces a biphasic activation of the 
enzyme as shown in Fig. 1. A first peak of activity is 
observed as early as 10 min after exposure of cells to 
IL-la (1 nM) and is followed by a second increase in 
activity which steadily increases over 24 h (Fig. 1). The 
degree of activation of MAP kinase, measured after 10 
min exposure of mesangial cells to IL-l/3 is concentra- 
tion-dependent (Fig. 2) and is paralleled by an increased 
phosphorylation of p42 MAP kinase as determined by 
immunoprecipitation from 32Pi-labelled mesangial cells 
(Fig. 3). To study whether IL-la has an effect on de novo 
synthesis of MAP kinase, mesangial cells were stimulated 
with IL-lp (1 nM) for different time periods and 
MAP kinase activity (% of control) 
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Fig. 1. Kinetics of MAP kinase activation of IL-l/?. Confluent mesangial cells were stimulated with IL-lb (1 nM) for the indicated time periods and 
MAP kinase-stimulated MBP phosphorylation was measured as described in section 2. 
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Fig. 2. Concentration-dependency of IL-l/I stimulated MAP kinase 
activation. Confluent mesangial cells were stimulated for 2 min with the 
indicated concentrations of IL-IS and MAP kinase-stimulated MBP 
phosphorylation was measured as described in section 2. 
[35S]methionine was added for the last 4 h of the stimula- 
tion period. p42 MAP kinase was immunoprecipitated 
with a specific polyclonal antibody and subjected to 
SDS-PAGE. Whereas under basal conditions only a 
faint band of p42 MAP kinase labelling is detectable 
(Fig. 4), addition of IL-la dramatically increases biosyn- 
thesis of the enzyme after 4 and 8 h of stimulation (Fig. 
4). This increased de novo synthesis of p42 MAP kinase 
is also detectable by Western blot analysis as after 24 h 
stimulation of mesangial cells with IL-l/? (1 nM) there 
is an approximately 60% increase in p42 MAP kinase 
protein as evaluated by densitometry. 
4. Discussions 
IL-l is a major product of activated monocytes and is 
also released by many cell types, including mesangial 
cells, when exposed to an inflammatory environment. 
IL-l exerts a wide range of activities and contributes to 
the pathogenesis of haemodynamic shock, as well as to 
many inflammatory and degenerative diseases [23]. 
These biological activities of IL-l are initiated by binding 
of the cytokine to two types of IL-l receptors designated 
as IL-1R type I and type II. Although the cytoplasmic 
portions of both IL-l receptors do not contain kinase 
domains or motifs homologous to any other known sig- 
nalling system, rapid intracellular protein phosphoryla- 
tion occurs in response to IL-l stimulation [ 161. The 
nature of the primary signal triggered by IL-l receptor 
activation remains poorly understood and controversial 
[l], but it is clear that IL-l does stimulate protein kinase 
activity in a wide variety of different cell types. Recently, 
IL-l and tumour necrosis factor have been reported to 
induce rapid MAP kinase activation in fibroblasts and 
KB cells [16-l 81. We extend these studies and report that 
IL-l/3 triggers a biphasic activation of the MAP kinase 
signalling pathway with a first rapid peak at 10 min and 
a second sustained activation lasting for more than 24 h. 
In addition, IL-l/? stimulates de novo synthesis of p42 
MAP kinase and thus provides mesangial cells with an 
increased capacity to transmit signals via this key sig- 
nalling enzyme that has been shown to regulate diverse 
protein kinases, protein phosphatases, nuclear transcrip- 
tion factors and phospholipase A, [19-211. The IL-l- 
stimulated biosynthesis and activation of MAP kinase 
may contribute to the proliferative response [12,13] and 
the activation of phospholipase A, [4-61 that has been 
observed in mesangial cells in response to this cytokine. 
A coordinate, biphasic activation of MAP kinase has 
also been demonstrated in hamster fibroblasts exposed 
to thrombin and is paralleled by a biphasic increase in 
ribosomal S6 kinase activity [24]. The authors, however, 
did not check whether the second peak of MAP kinase 
activity is due to increased de novo synthesis of the en- 
zyme as shown here for mesangial cells. Obviously, a 
maintained signal flow along the MAP kinase cascade is 
required to drive a cell into mitosis [12,13] and to initiate 
other long- term cellular responses uch as phospholip- 
ase A, activation [&6]. In mesangial cells MAP kinase 
activation has been reported for endothelin, epidermal 
growth factor, thrombin [22] and for platelet-derived 
growth factor and extracellular nucleotides (Huwiler and 
Pfeilschifter, manuscript submitted) which all are potent 
mitogens. The mechanisms by which IL-l stimulates 
MAP kinase activation and biosynthesis are unknown 
and tracing this signalling cascade more upstream may 
help to unravel the primary signalling event triggered by 
IL-l. Recently, Saklatvala and colleagues [25] reported 
that IL-l and tumour necrosis factor activate MAP ki- 
nase kinase in fibroblasts and KB cells. Whether the 
cytokines do so by activating c-Raf kinase or MAP ki- 
nase kinase kinase remains to be evaluated. Additional 
studies are also required to determine the pathophysiol- 
ogical significance of IL-l/?-stimulated de novo synthesis 
of MAP kinase in mesangial cells and its possible role in 
inflammatory kidney diseases. 
Fig. 3. IL-IS stimulates p42 MAP kinase phosphorylation. Mesangial 
cells labelled with [“PJorthophosphate were stimulated with vehicle (co) 
or IL-I,fI (1 nM) for IO min. Cells were then lysed and p42 MAP kinase 
was immunoprecipitated with a specific antiserum at a dilution of 1:200. 
The immunoprecipitates were separated on SDS-PAGE (10% 
acrylamide gel) and exposed to Hyperfilm MP. 
138 
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Fig. 4. Kinetics of IL-l/?-stimulated MAP kinase de novo synthesis. 
Confluent mesangial cells were stimulated with vehicle (co) for 8 h or 
IL-lp (1 nM) for the indicated time periods. During the last 4 h 
[%]methionine was added. Then p42 MAP kinase was immunoprecip- 
itated as measured as described in section 2. 
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